The American Journal of Cardiology, Journal Year: 2024, Volume and Issue: 215, P. 78 - 79
Published: Jan. 5, 2024
Language: Английский
Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)
Published: July 22, 2024
Abstract Background Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits. Previous studies in apolipoprotein E knockout mice have shown that SGLT2i associated attenuated progression of atherosclerosis. However, whether this effect extends to T2DM patients coronary atherosclerosis real-world settings remains unknown. Methods In longitudinal cohort study using computed tomography angiography (CCTA), who underwent ≥ CCTA examinations at our center between 2019 and 2022 were screened. Eligible had multiple plaques, defined as non-obstructive stenosis baseline not intervened during serial CCTAs. Exclusion criteria included time interval < 12 months, prior treatment, or initiation/discontinuation Plaque volume (PV) percent atheroma (PAV) measured each plaque analysis software. Patients plaques categorized based on therapy compared 1:1 propensity score matching (PSM) analysis. Results The 236 (mean age 60.5 ± 9.5 years; 69.1% male) 435 (diameter 50%, 31.7%). Following treatment median duration 14.6 (interquartile range: 13.0, 20.0) overall, non-calcified, low-attenuation PV PAV significantly decreased, while calcified increased (all p 0.001). Meanwhile, reductions overall PV, non-calcified PAV, greater SGLT2i-treated non-SGLT2i-treated PSM showed was higher (− 11.77 mm 3 vs. 4.33 , = 0.005), 16.96 − 1.81 0.017), 2.83% 3.36%, 0.001), 4.60% 0.70%, 0.003). These findings remained consistent when assessing annual changes compositional PAV. Multivariate regression models even after adjusting risk factors, medications, respectively 0.05). attenuating across subgroups interaction > Conclusions patients, markedly regressed mainly result from significant reduction plaque. Graphical abstract
Language: Английский
Citations
6
Current Hypertension Reports, Journal Year: 2024, Volume and Issue: 26(12), P. 463 - 474
Published: June 24, 2024
Purpose of Review Chronic kidney disease and end-stage (ESKD) are well-established risk factors for cardiovascular (CVD), the leading cause mortality in dialysis population. Conventional therapies, such as statins, blood pressure control, renin-angiotensin-aldosterone system blockade, have inadequately addressed this risk, highlighting unmet need effective treatment strategies. Sodium–glucose transporter 2 (SGLT2) inhibitors demonstrated significant renal benefits among patients with type diabetes, heart failure, or CKD at progression. Unfortunately, efficacy data is lacking ESKD was an exclusion criterion all major clinical trials SGLT2 inhibitors. This review explores potential improving outcomes ESKD, focusing on their direct cardiac effects. Recent Findings preclinical studies shown promising application to may provide patients, not only indirectly by preserving remaining function anemia but also directly lowering intracellular sodium calcium levels, reducing inflammation, regulating autophagy, alleviating oxidative stress endoplasmic reticulum within cardiomyocytes endothelial cells. Summary examines current evidence experimental supporting use inhibitors, discusses its safety concerns, outlines ongoing Further research needed evaluate effectiveness inhibitor ESKD.
Language: Английский
Citations
5
Pharmacological Research, Journal Year: 2024, Volume and Issue: 205, P. 107246 - 107246
Published: June 5, 2024
Language: Английский
Citations
4
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: April 11, 2024
The aim of this systematic review and meta-analysis was to investigate the impact early sodium-glucose cotransporter-2 (SGLT2) initiation on long-term cardiovascular outcomes all-cause mortality among patients with acute coronary syndrome (ACS). For study, we adhered Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) 2020 guideline. Two researchers independently performed a comprehensive literature search PubMed, Embase, Cochrane Library, spanning from inception each database February 24, 2023, without language limitations. examined in comprised major adverse events (MACE) (as defined by individual studies), mortality, stroke (ischemic hemorrhagic), recurrent ACS, hospitalization due heart failure (HF). A total nine studies were included meta-analysis. pooled analysis revealed significant reduction risk MACE, cardiovascular-related hospitalizations receiving SGLT2 inhibitors (SGLT2i) compared those control group. Additionally, there trend toward lower ACS SGLT2i group, although difference did not reach statistical significance. findings study suggest promising therapeutic effect population. Further research, particularly focusing myocardial infarction (MI) patients, is warranted validate these results potentially revolutionize management.
Language: Английский
Citations
3
The American Journal of the Medical Sciences, Journal Year: 2025, Volume and Issue: unknown
Published: May 1, 2025
Language: Английский
Citations
0
The American Journal of Cardiology, Journal Year: 2024, Volume and Issue: 222, P. 95 - 95
Published: May 7, 2024
Language: Английский
Citations
0
The American Journal of Cardiology, Journal Year: 2024, Volume and Issue: 215, P. 78 - 79
Published: Jan. 5, 2024
Language: Английский
Citations
0